



OxySure Systems, Inc. (OXYS)

2Q 2014 Financial Results

August 15, 2014

It's About Time.

Forward Looking Statements

The following may contain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this communication, including statements relating to our growth strategy, financial results, product approvals, and development programs, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance to differ materially from the forward-looking statements we make include: range of treatment options, clinical applications, and market acceptance of products and other risks detailed from time to time in our filings with the Securities and Exchange Commission. Our actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors.




2Q 2014 Financial Highlights

- Revenues were \$678,111, up 42%
- Gross profit up \$89,656 or 27.7% to \$413,255
- Other income up 123% to \$42,465
- SG&A up 26% to \$689,248
- Net loss per share flat at \$.01 for the quarter
- Model 615 shipments up 65%




2Q 2014 Financial Results – c

YOY Results – 2Q14 v 2Q13 (in thousands)



2Q 2014 Financial Results - 3 Months

Q/Q Results – 1Q14 v 1Q13 (in thousands)



2Q 2014 Financial Results - 3 Months


YOY Results – 2Q14 v 2Q13 (in thousands)

2Q 2014	2Q 2013
Revenues:	
\$678,111	\$476,071
Net income (loss):	
\$(275,993)	\$(224,229)
Net income (loss) per share:	
\$(.01)	\$(.01)



2Q 2014 Financial Results – 6 Months

YOY Results – 2Q14 v 2Q13 (in thousands)



Replacement cartridge sales



OxySure Model 615, US version



Replacement cartridge for OxySure Model 615



OxySure Model 615, Europe version



Open the Lid



Remove Expended Cartridge



Replace with New Cartridge & Remove Safety Tabs

Consolidated Balance Sheets

	6/30/2014	12/31/2013
<u>ASSETS</u>		
Current assets		
Cash and cash equivalents	\$ 21,981	\$ 657,673
Accounts receivable, net of allowances for sales returns and allowance for doubtful accounts	410,726	47,183
Inventories	285,862	287,666
License fees receivable	463,308	500,000
Prepaid expenses and other current assets	48,433	107,305
Total current assets	1,230,310	1,599,827
Property and equipment, net	131,113	70,249
Intangible assets, net	377,878	392,746
Other assets	285,895	289,532
TOTAL ASSETS	\$ 2,025,196	\$ 2,352,354



Consolidated Balance Sheets, cont.

<u>LIABILITIES AND STOCKHOLDERS' EQUITY</u>		
Current liabilities		
Accounts payable and accrued expenses	\$ 436,450	\$ 147,719
Related party payable	24,501	118,627
Deferred revenue	-	2,976
Capital leases - current	308,121	309,129
Notes payable - current, net of discount	37,794	44,000
Convertible notes payable, net of discount	306,053	229,903
Total current liabilities	1,112,919	852,354
Long-term liabilities		
Capital leases	554	554
Notes payable, net of discount	44,484	76,072
Total long-term liabilities	45,038	76,626
TOTAL LIABILITIES	1,157,957	928,980
<u>STOCKHOLDERS' EQUITY</u>		
Preferred stock, par value \$0.0005 per share; 25,000,000 shares authorized;		
643,750 Series A convertible preferred shares issued and outstanding as of June 30, 2014 and 743,750 shares issued and outstanding as of December 31, 2013.	321	371
750 Series B convertible preferred shares issued and outstanding as of March 31, 2014 and 750 shares issued and outstanding as of December 31, 2013.	-	-
Common stock, par value \$0.0004 per share; 100,000,000 shares authorized;		
26,074,598 shares of voting common stock issued and outstanding as of June 30, 2014 and 25,854,307 shares issued and outstanding as of December 31, 2013	10,432	10,343
Additional Paid-in Capital	16,839,961	16,700,307
Accumulated deficit	(15,983,475)	(15,287,647)
TOTAL STOCKHOLDERS' EQUITY	867,239	1,423,374
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 2,025,196	\$ 2,352,354



Statement of operations

	For the three months ended June 30,	
	2014	2013
Revenues, net	\$ 678,111	\$ 476,071
Cost of goods sold	264,856	152,472
Gross profit	413,255	323,599
Operating expenses		
Research and development	275,974	183,447
Sales and marketing	154,044	133,730
Other general and administrative	259,230	230,651
Loss from operations	(275,993)	(224,229)
Other income (expenses)		
Other income (expense)	42,465	19,026
Interest expense	(85,980)	(26,734)
Total other income (expenses)	(43,515)	(7,708)
Net loss	\$ (319,508)	\$ (231,937)
Basic net income (loss) per common share	\$ (0.01)	\$ (0.01)
Diluted net income (loss) per common share	\$ (0.01)	\$ (0.01)
Weighted average common shares outstanding:		
Basic and diluted	25,996,642	23,167,439

Looking ahead...

- Close on 3 overseas launches
- Multiple new, overseas distribution agreements
- Direct to consumer plan
- Second Australian approval
- New US distributors
- Management expansion
- Asset tracking and incident reporting



Summary

- Excellent building quarter
- Well balanced growth and bottom line objectives
- Diversification is paying dividends
- Progress on all fronts, including strategic long term goals

2Q 2014 Financial Results

OxySure Systems, Inc. (OXYS)

investors@oxysure.com

www.oxysure.com

Questions & Answers



Contact Information

OxySure Systems, Inc.

OXYS: OTCQB

10880 John W. Elliott Road, Suite 600

Frisco, TX 75034 USA

Tel: (+1) 972-294-6450

info@oxysure.com

www.OxySure.com



Stonegate Securities, Inc.

(214) 987-4121

investors@oxysure.com

<http://www.stonegateinc.com/>

Renmark Financial Communications, Inc.

(416) 644-2020

Bettina Filippone: bfilippone@renmarkfinancial.com

John Boidman: jboidman@renmarkfinancial.com

www.renmarkfinancial.com/

